SubsídioEuropean Commission

Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

Sobre este edital

Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or multi-modal treatment interventions via participation in subsequent clinical trials or national or regional compassionate use programmes by health authorities; Researchers, physicians, innovators [1] , startup, spin-off and spin-out companies, SMEs, charities or foundations and other professionals fro…

Fonte

Estes dados vêm de ec.europa.eu. Confira ali a elegibilidade e o prazo antes de se candidatar.